Rat engineered heart tissue: a novel tool in the safety pharmacology toolkit?

Basic Research in Cardiology

Volumn 109, Issue 6, 2014, Pages

  Heijman, Jordi ^a   Dobrev, Dobromir ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; DELAYED RECTIFIER POTASSIUM CHANNEL;

ACTION POTENTIAL DURATION; ARRHYTHMOGENESIS; CALCIUM TRANSPORT; DRUG SAFETY; EDITORIAL; EMBRYONIC STEM CELL; ERG GENE; GENE; GENE MUTATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HUMAN; IN VIVO STUDY; KCNQ1 GENE; NON INVASIVE PROCEDURE; NONHUMAN; PLURIPOTENT STEM CELL; TISSUE ENGINEERING; TORSADE DES POINTES; ANIMAL; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED; CYTOPLASM; DRUG EFFECTS; DRUG MONITORING; HEART; PROCEDURES; RAT;

ANIMALS; ARRHYTHMIAS, CARDIAC; DRUG MONITORING; HEART; ORGANOIDS; RATS; TISSUE ENGINEERING;

EID: 84911387586     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-014-0437-6     Document Type: Editorial

References (23)

1. Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, Geldenhuys G, Vanoli E, Bacchini S, Spazzolini C, Lundquist AL, Roden DM, George AL Jr, Schwartz PJ (2005) Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation 112:2602–2610. doi:10.1161/CIRCULATIONAHA.105.572453
2. Crocini C, Arimura T, Reischmann S, Eder A, Braren I, Hansen A, Eschenhagen T, Kimura A, Carrier L (2013) Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue. Basic Res Cardiol 108:349. doi:10.1007/s00395-013-0349-x
3. 2+ signaling. J Mol Cell Cardiol 46:448–451. doi:10.1016/j.yjmcc.2008.12.004
4. Eder A, Hansen A, Uebeler J, Schulze T, Neuber C, Schaaf S, Yuan L, Christ T, Vos MA, Eschenhagen T (2014) Effects of proaarhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. Basic Res Cardiol (this issue)
5. Grace AA, Roden DM (2012) Systems biology and cardiac arrhythmias. Lancet 380:1498–1508. doi:10.1016/S0140-6736(12)61462-7
6. Heijman J, Voigt N, Carlsson LG, Dobrev D (2014) Cardiac safety assays. Curr Opin Pharmacol 15:16–21. doi:10.1016/j.coph.2013.11.004
7. Heijman J, Voigt N, Nattel S, Dobrev D (2014) Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res 114:1483–1499. doi:10.1161/CIRCRESAHA.114.302226
8. Hoffmann P, Warner B (2006) Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 53:87–105. doi:10.1016/j.vascn.2005.07.003
9. Johnson DM, Heijman J, Bode EF, Greensmith DJ, van der Linde H, Abi-Gerges N, Eisner DA, Trafford AW, Volders PG (2013) Diastolic spontaneous calcium release from the sarcoplasmic reticulum increases beat-to-beat variability of repolarization in canine ventricular myocytes after beta-adrenergic stimulation. Circ Res 112:246–256. doi:10.1161/CIRCRESAHA.112.275735
10. Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T, Holloway C, McMahon N, Milligan J, Park B, Pirmohamed M, Pollard C, Radford J, Roome N, Sager P, Singh S, Suter T, Suter W, Trafford A, Volders P, Wallis R, Weaver R, York M, Valentin J (2011) How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol 163:675–693. doi:10.1111/j.1476-5381.2011.01255.x
11. McKernan R, Watt FM (2013) What is the point of large-scale collections of human induced pluripotent stem cells? Nat Biotechnol 31:875–877. doi:10.1038/nbt.2710
12. Meyer T, Sartipy P, Blind F, Leisgen C, Guenther E (2007) New cell models and assays in cardiac safety profiling. Expert Opin Drug Metab Toxicol 3:507–517. doi:10.1517/17425225.3.4.507
13. Nattel S, Dobrev D (2012) The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 33:1870–1877. doi:10.1093/eurheartj/ehs079
14. Neef S, Maier LS (2013) Novel aspects of excitation–contraction coupling in heart failure. Basic Res Cardiol 108:360. doi:10.1007/s00395-013-0360-2
15. Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenpera M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikstrom BG, Jorgensen K, Filippatos G, Parissis JT, Gonzalez MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 159:82–87. doi:10.1016/j.ijcard.2011.07.022
16. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15–19. doi:10.1136/bmj.329.7456.15
17. Rampe D, Brown AM (2013) A history of the role of the hERG channel in cardiac risk assessment. J Pharmacol Toxicol Methods 68:13–22. doi:10.1016/j.vascn.2013.03.005
18. Sauer AJ, Newton-Cheh C (2012) Clinical and genetic determinants of torsade de pointes risk. Circulation 125:1684–1694. doi:10.1161/CIRCULATIONAHA.111.080887
19. Schaaf S, Shibamiya A, Mewe M, Eder A, Stohr A, Hirt MN, Rau T, Zimmermann WH, Conradi L, Eschenhagen T, Hansen A (2011) Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 6:e26397. doi:10.1371/journal.pone.0026397
20. Stöhr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T (2013) Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J Mol Cell Cardiol 63:189–198. doi:10.1016/j.yjmcc.2013.07.011
21. Tsuji Y, Heijman J, Nattel S, Dobrev D (2013) Electrical storm: recent pathophysiological insights and therapeutic consequences. Basic Res Cardiol 108:336. doi:10.1007/s00395-013-0336-2
22. Kr block is insufficient to detect Torsades de pointes liability: role of Late sodium current. Circulation. doi:10.1161/CIRCULATIONAHA.113.007765
23. + channel in rat ventricular cells. J Pharmacol Exp Ther 283:375–383